This inventor holds 2 USPTO granted patents. Top assignees: Aventis Pharma Deutschland, Gmbh, Hoechst Aktiengesellschaft. Active years: 1999-2001.
Company Filing History:
1 out of 330 
1 out of 6,705 
Years Active: 1999-2001
Title: Bruce Caterson: Innovator in Recombinant Substrates
Introduction
Bruce Caterson is a notable inventor based in Wales, GB. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant substrates for aggrecanase. With a total of 2 patents, his work has implications for understanding and treating osteoarthritis.
Latest Patents
Caterson's latest patents include the invention of an artificial recombinant substrate (rAGG 1) and native aggrecan to determine the proteolytic activity of 'aggrecanase' in cell culture systems. This invention relates to novel recombinant substrates for aggrecanase, which comprise various components such as the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, and the interglobular domain of human aggrecan. Additionally, the invention provides DNA sequences encoding the recombinant substrate, vectors, and host cells containing said DNA. Various methods are outlined for monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and screening for aggrecanase inhibitors. A diagnostic aid containing the recombinant substrate is also included in his patents.
Career Highlights
Throughout his career, Bruce Caterson has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable among these are Hoechst Aktiengesellschaft and Aventis Pharma Deutschland, GmbH. His experience in these organizations has contributed to his expertise in the field.
Collaborations
Caterson has collaborated with esteemed colleagues such as Frank Buettner and Eckart Bartnik. These partnerships have likely enriched his research and development efforts.
Conclusion
Bruce Caterson's innovative work in recombinant substrates has the potential to advance our understanding of aggrecanase and its role in osteoarthritis. His contributions to biotechnology are noteworthy and continue to influence the field.